Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer


Tas F. , Derin D., Guney N. , Aydiner A. , Topuz E.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, ss.330-334, 2008 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 13 Konu: 4
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1007/s10147-007-0757-8
  • Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • Sayfa Sayıları: ss.330-334

Özet

Background. Pegylated liposomal doxorubicin (PLD) is the only nonplatinum agent to significantly improve survival in patients with platinum-sensitive recurrent ovarian cancer. The present study was designed to assess the efficacy and safety of PLD plus cisplatin combination therapy in these patients.